Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series
Brain & Development
· Elsevier
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Читать у издателя →
Цитировать
Получайте новые статьи по теме «Педиатрия, перинатология и детское здоровье»
Подписка, поиск по ключевым словам и избранное — в Telegram-боте Articlium.
Открыть в Telegram
Цитирование
✕
ГОСТ
APA
MLA
BibTeX
Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series. // Brain & Development. – URL: https://www.sciencedirect.com/science/article/pii/S0387760426000999?dgcid=rss_sd_all
Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series. Brain & Development. https://www.sciencedirect.com/science/article/pii/S0387760426000999?dgcid=rss_sd_all
“Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series.” Brain & Development.
@article{article38860,
title = {Third-line tocilizumab for refractory pediatric anti-NMDA receptor encephalitis: a single-center case series},
journal = {Brain \& Development},
url = {https://www.sciencedirect.com/science/article/pii/S0387760426000999?dgcid=rss_sd_all}
}